Active Pharmaceutical Ingredient API News and Research

RSS

Non-destructive screening method enables quick, safe identification of pharmaceutical tablet properties

Information on significant properties of pharmaceutical tablets, such as their mechanical strength and dissolution, can now be obtained without resorting to the conventional, time-consuming and destructive testing methods, according to a new study completed at the University of Eastern Finland.

11 Jan 2017

New active pharmaceutical ingredient may help against severe forms of testicular cancer

A new active pharmaceutical ingredient may help against severe forms of testicular cancer, which only respond inadequately to other therapies.

30 Dec 2016

CPhI Pre-Connect Congress to provide insights on major developments in pharmaceutical industry

CPhI Worldwide, organized by UBM EMEA, announces the upcoming trends in the 8th edition of the CPhI Pre-Connect Congress, taking place on October 3rd.

26 Aug 2016

Researchers aim to improve medical treatment for people with insect venom allergy

A team of researchers has elucidated individual profiles of allergy reactivity in patients that are not protected after treatment with immunotherapy. The aim is to improve medical treatment of people who are allergic to insect stings.

21 Jun 2016

RedHill Biopharma initiates phase II study of BEKINDA for irritable bowel syndrome

RedHill Biopharma Ltd. (NASDAQ; RDHL) (TASE: RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including cancer, today announced that it has initiated a randomized, double-blind, 2-arm parallel group Phase II clinical study in the U.S. evaluating the safety and efficacy of BEKINDA™ 12 mg in patients with diarrhea-predominant irritable bowel syndrome (IBS-D).

13 Apr 2016

Aralez resubmits NDA package for YOSPRALA to FDA

Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company, today announced that it has resubmitted to the U.S. Food and Drug Administration the New Drug Application ("NDA") for its investigational candidate, YOSPRALA (PA32540/PA8140) for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers.

15 Mar 2016

AMRI's net revenues increase $126.4M to 46% in fourth quarter 2015

AMRI today reported financial and operating results for the fourth quarter and full year ended December 31, 2015 and provided an outlook for 2016.

17 Feb 2016

DS Biopharma reports completion of DS102 Phase I trial for treatment of fatty liver disorders

DS Biopharma, a privately held biopharmaceutical company, today announced the successful completion of a Phase I trial with an oral formulation of the active pharmaceutical ingredient DS102 (15-HEPE) which is being explored for the treatment of fatty liver disorders, such as non-alcoholic steatohepatitis (NASH) and pulmonary disorders, such as idiopathic pulmonary fibrosis (IPF).

18 Dec 2015

Egalet submits NDA for ARYMO ER (morphine sulfate) extended-release tablets

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, announced the company has submitted a new drug application (NDA) for ARYMO ER (morphine sulfate) extended-release tablets for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.

15 Dec 2015

Most drug residues discharged to wastewater come from private households

Most drug residues discharged to wastewater come from private households. As contributors of pollution by Active Pharmaceutical Ingredients (APIs), health establishments, such as hospitals, psychiatric and nursing facilities are hardly worth mentioning.

20 Oct 2015

Sikka Software's cloud-based practice optimization platform transforms retail healthcare industry

Retail healthcare is a $220 billion industry, representing over 2.1 million providers and 400 million patients in just 5 markets of US, UK, Canada, Australia and New Zealand. Sikka Software, a leading innovator in business intelligence software for the retail healthcare industry, today announced its cloud-based practice optimization platform is helping practices increase revenue and profitability by leveraging key information from existing customer data.

30 Sep 2015

Collaborative approach may speed discovery of new preventive treatments for Alzheimer's disease

The future success of Alzheimer's prevention research could depend on the ability of researchers from different clinical trials to build collaborative relationships that facilitate the sharing of information, resources and expertise that may speed the discovery of new preventive treatments, according to leading Alzheimer's researchers who published a Perspectives article, "CAP--advancing the evaluation of preclinical Alzheimer disease treatments," online today in Nature Reviews Neurology.

30 Sep 2015

TUM, Stanford University scientists create new cancer therapy concept

Pancreatic cancer is one of the most aggressive forms of cancer and one of the most difficult to treat. Its high resistance to treatment is a major problem, particularly in the advanced stages.

24 Sep 2015

New Locilex microbiology data presented at ICAAC/ICC 2015 scientific conference

Dipexium Pharmaceuticals, Inc., a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.8%), and research collaborators, JMI Laboratories, announced that new Locilex microbiology data were presented at the American Society for Microbiology's Interscience Conference of Antimicrobial Agents and Chemotherapy and International Society of Chemotherapy's International Congress of Chemotherapy and Infection (ICAAC/ICC 2015) scientific conference in San Diego, California, September 17-21, 2015.

21 Sep 2015

CPhI reports positive outlook on the Chinese pharmaceutical market

CPhI – a division of UBM EMEA – alongside UBM Sinexpo, announces the findings of the Pharma Insights China 2015 report.

13 Aug 2015

Dipexium reports net loss of $4.0 million for second quarter 2015

Dipexium Pharmaceuticals, Inc., a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.8%), a novel, broad-spectrum, topical antibiotic peptide, today reported financial results for the quarter ended June 30, 2015.

13 Aug 2015

Global Pharmaceutical Contract Manufacturing market estimated to reach $84 billion in 2020

Mordor Intelligence releases their report on the Global Pharmaceutical Contract Manufacturing market is segmented by Dose Formulation type (Solid Dose Formulation, Liquid Dose Formulation, Injectable Dose Formulation - By Geographical Region (North America, Europe, Latin America, APAC, Middle East & Africa) - Drivers, Restraints, Vendor Profiles, Global Market Size, Forecasts & Analysis (2015-2020).

10 Aug 2015

AMRI’s total revenue increases $89.5 million to 31% in second quarter 2015

AMRI today reported financial and operating results for the second quarter ended June 30, 2015. "We are very pleased to present another strong financial quarter, with all our divisions achieving excellent results," said William S. Marth, AMRI's president and chief executive officer. "Notably, recent acquisitions, combined with the cost reduction initiatives and efficiency efforts we've made to date, are contributing to continued strong contract margin performance.

4 Aug 2015

European Commission grants orphan drug designation to SGX301 for treatment of CTCL

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orphan Medicinal Products (COMP), has granted orphan drug designation to synthetic hypericin (the active pharmaceutical ingredient in SGX301) for the treatment of cutaneous T-cell lymphoma (CTCL), a rare disease and a class of non-Hodgkin's lymphoma, a type of cancer of the white blood cells that are an integral part of the immune system.